ELTX · Elicio Therapeutics, Inc.

Elicio Therapeutics Inc Is A Clinical-Stage Biotechnology Company Advancing Novel Immunotherapies For The Treatment Of Cancer, Including Mkras-Positive Pancreatic Cancer, Colorectal Cancer (Crc), Lung Cancer, And Other Mkras-Positive Cancers. The Company Focuses On Developing Effective, Off-The-Shelf Immunotherapies Using Its Proprietary Amphiphile (Amp) Technology, Which Aims To Enhance The Education, Activation, And Amplification Of Cancer-Specific T Cells To Promote Durable Cancer Immunosurveillance. Its Clinical Pipeline Includes Eli-002 7p, A Lymph Node-Targeted Cancer Immunotherapy Currently Being Evaluated In A Phase 2 Study For Mkras Pancreatic Ductal Adenocarcinoma (Pdac), A Common Form Of Pancreatic Cancer.